The specialist small molecule drug development Company has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new treatment for autoimmune diseases. The Company is also completing its assessment of promising dual TYK2/JAK1 inhibitors for the potential treatment of certain cancers and expects to nominate a lead candidate in the near future.
